Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories
Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

February 15, 2021 Banking and Finance Capital Markets and Public M&A M&A

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge advises Precise Biometrics in connection with rights issue
July 24, 2026

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

 Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026